Dr Reddy's growth strategy focuses on differentiated portfolio in key therapy areas

24 March 2023

Indian generic drug major Dr Reddy's Laboratories (DRL; BSE: 500124) has been strategizing to become a top company in the Indian pharmaceutical market. The company’s focus is on building strong brands and excelling in selected therapy areas.

In line with this goal, the company has been divesting non-core brands that do not align with its growth objectives and acquiring product rights from other companies to strengthen its portfolio. The company’s differentiated approach to its product offerings is a key part of growth strategy in India, says data and analytics company GlobalData.

Recent transactions

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK